Projects per year
Personal profile
Personal profile
Dr. Aparna Kamat is the director of the Division of Gynecologic Oncology for Houston Methodist and is currently the section leader for the Gynecologic Oncology service line. After completing medical training in India, Dr. Kamat completed her residency in OB/GYN at West Virginia University where she served as chief resident.
She completed her fellowship training in Gynecologic Oncology at the MD Anderson Cancer Center. During her fellowship, she received multiple awards for her research in ovarian cancer and endometrial cancer including the Virginia K. Pierce award and the Asche Murray fellowship. She also received the prestigious BIRCWH award from the N.I.H. for her research in biomarkers for ovarian cancer. Dr. Kamat currently is the principle investigator for the Gynecologic Oncology Group Clinical Trials Program at Houston Methodist and offers several state-of-the-art clinical trials for patients with gynecologic malignancies.
Her areas of expertise are robotic and minimally invasive surgical options for women with gynecologic cancers and complex pelvic disease. Her other clinical interests include hereditary risk assessment and treatment of gynecologic malignancies.
Research Area Keywords
- Cancer
Free-text keywords
- Gynecologic cancer
- Pelvic disease
- Hereditary risk assessment
- Minimally invasive surgery
- Gynecologic malignancy
Fingerprint
Dive into the research topics where Aparna A. Kamat is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 6 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Projects
- 22 Active
-
GOG-3044 LAE002INT2001
Kamat, A. A., Alaniz, A., Darcourt, J., Singh, M., Suri, A. & Zaid, T.
4/16/21 → …
Project: Clinical Trial
-
Clinical Validation of the InterVenn Ovarian CAncer Liquid Biopsy (VOCAL)
Kamat, A. A., Alaniz, A., Suri, A. & Zaid, T.
3/12/20 → …
Project: Clinical Trial
Research output
-
Erratum: Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy (Clin Cancer Res (2019) 12(4916–4924)Doi:10.1158/1078-0432.CCR-06-0021)
Halder, J., Kamat, A. A., Landen, C. N., Han, L. Y., Lutgendorf, S. K., Lin, Y. G., Merritt, W. M., Jennings, N. B., Chavez-Reyes, A., Coleman, R. L., Gershenson, D. M., Schmandt, R., Cole, S. W., Lopez-Berestein, G. & Sood, A. K., 2019, In: Clinical Cancer Research. 25, 10, p. 3194 1 p.Research output: Contribution to journal › Comment/debate › peer-review
-
Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial
TRINOVA-3/ENGOT-ov2/GOG-3001 investigators, Jun 2019, In: The Lancet Oncology. 20, 6, p. 862-876 15 p.Research output: Contribution to journal › Article › peer-review
25 Scopus citations -
Non-16/18 high-risk HPV infection predicts disease persistence and progression in women with an initial interpretation of LSIL
Lyons, Y. A., Kamat, A. A., Zhou, H., Mody, D. R., Schwartz, M. R., Hobday, C. & Ge, Y., Jul 2015, In: Cancer cytopathology. 123, 7, p. 435-442 8 p.Research output: Contribution to journal › Article › peer-review
9 Scopus citations -
Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma
Gillet, J. P., Calcagno, A. M., Varma, S., Davidson, B., Elstrand, M. B., Ganapathi, R., Kamat, A. A., Sood, A. K., Ambudkar, S. V., Seiden, M. V., Rueda, B. R. & Gottesman, M. M., Jun 1 2012, In: Clinical Cancer Research. 18, 11, p. 3197-3206 10 p.Research output: Contribution to journal › Article › peer-review
36 Scopus citations -
Ovarian cancer
Bhosale, P., Kamat, A. & Eifel, P. J., Jan 1 2012, Oncologic Imaging: A Multidisciplinary Approach. Elsevier Health Sciences, p. 455-478 24 p.Research output: Chapter in Book/Report/Conference proceeding › Chapter
1 Scopus citations